Cue Biopharma (CUE) Cash & Current Investments (2017 - 2025)

Cue Biopharma has disclosed Cash & Current Investments across 9 years of filings, most recently posting $27.7 million for Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $27.7 million, up 18.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.7 million (up 18.41% YoY), and the FY2025 annual result was $27.7 million, up 18.41% from the prior year.
• Cash & Current Investments came in at $27.7 million for Q4 2025 at Cue Biopharma, up from $18.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $76.3 million in Q4 2022 to a low of $14.0 million in Q1 2025.
• The 5-year median for Cash & Current Investments is $53.4 million (2021), against an average of $48.9 million.
• Across the five-year window, Cash & Current Investments jumped 50.33% in 2021 and slumped 65.76% in 2025, its largest moves.
• Cue Biopharma's Cash & Current Investments stood at $52.2 million in 2021, then surged by 46.12% to $76.3 million in 2022, then tumbled by 36.03% to $48.8 million in 2023, then slumped by 52.07% to $23.4 million in 2024, then advanced by 18.41% to $27.7 million in 2025.
• The last three Cash & Current Investments figures came in at $27.7 million (Q4 2025), $18.2 million (Q3 2025), and $28.0 million (Q2 2025), per Business Quant data.